Skip to content
Clinical Trials – home
SwedenBack to Sweden

Clinical trials in Helsingborg – page 10

1 322 clinical trials in Helsingborg, Sweden. Every trial is listed in the EU Clinical Trials Register and updated daily.

SwedenOur site in SwedenKliniska-Provningar.se(opens in a new tab)
Helsingborg at a glance
1 322
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 322 trials in Helsingborg

Open in trial search

Venetoclax added to fludarabine, cytarabine and gemtuzumab ozogamicin (drug combination) in children with relapsed acute myeloid leukemia

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:0–17 years · 18–64 years
  • Substances:Azacitidine
  • Sponsor:Prinses Maxima Centrum voor Kinderoncologie B.V.

Measles+3

Recruiting

Long‑term immunity after a 6‑month‑old MMR vaccine (live attenuated) in infants: follow‑up of antibody levels 1‑3 years after routine vaccination

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:0–17 years · Healthy volunteers
  • Substances:MUMPS VIRUS RIT 4385 STRAIN (LIVE, ATTENUATED) DERIVED FROM FROM THE JERYL LYNN PRODUCED IN CHICK EMBRYO CELLS
  • Sponsor:Region Hovedstaden

A Phase 2/3 Study of intravitreal mk-8748 versus aflibercept in adults with neovascular age‑related macular degeneration

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept
  • Sponsor:Eyebiotech Limited

Evaluation of NXT007 versus Emicizumab Prophylaxis in Patients with Hemophilia A

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Emicizumab
  • Sponsor:F. Hoffmann-La Roche AG

A Phase III study of NXT007 compared with simoctocog alfa prophylaxis in patients with Hemophilia A without inhibitors

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:RO7589655
  • Sponsor:F. Hoffmann-La Roche AG

Long‑Term Safety and Efficacy of RO7790121 in Adults with Moderate to Severe Rheumatoid Arthritis: Extension Study

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:RO7790121
  • Sponsor:F. Hoffmann-La Roche AG

Crohn's disease

Recruiting

A Phase 3b Study of Guselkumab Compared with Risankizumab in Adults with Moderately to Severely Active Crohn’s Disease

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Guselkumab
  • Sponsor:Janssen Cilag International

Neoplasm

Recruiting

Safety and Efficacy of Ifinatamab Deruxtecan in Pediatric Patients Under 18 With Relapsed or Refractory Solid Tumors

InvestigationalNo placebo
Countries:SwedenSweden
  • Participants:0–17 years
  • Substances:Ifinatamab Deruxtecan
  • Sponsor:Merck Sharp & Dohme LLC

Sepsis+1

Recruiting

Acetylcysteine for Adults with Acute Infection or Sepsis and Liver Dysfunction

Registered drug
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Acetylcysteine
  • Sponsor:Region Hovedstaden

Nipocalimab in Adults with Moderate to Severe Systemic Lupus Erythematosus

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Nipocalimab
  • Sponsor:Janssen Cilag International

Neoplasm

Recruiting

Telisotuzumab Adizutecan for Locally Advanced or Metastatic Solid Tumors with MET Amplification in Patients 12 Years and Older

InvestigationalNo placebo
Countries:DenmarkDenmark
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Telisotuzumab adizutecan
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Neoplasm

Recruiting

EIK1005 Alone and with Pembrolizumab for Advanced Solid Tumors in Patients with MSI-H or dMMR Tumors

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:EIK1005 sodium
  • Sponsor:Eikon Therapeutics Inc.

Other cities in Sweden

The busiest research cities in the country

All 66 cities in Sweden

Clinical research in Helsingborg

What the registry says about research in the country

01 Cardiovascular Research

Innovative studies exploring treatments for heart failure and cardiovascular conditions, including research on combination therapies to reduce cardiovascular mortality.

  • Heart Failure Prevention
  • Atrial Fibrillation
  • Takotsubo Syndrome

Groundbreaking trials evaluating novel drug combinations and therapeutic approaches for cardiac conditions.

02 Oncology Studies

Advanced research focusing on multiple myeloma treatment, particularly for patients with relapsed or refractory conditions.

  • Blood Cancer Therapies
  • Combination Treatment Approaches
  • Bladder Cancer Management

Evaluating innovative therapeutic combinations and comparing effectiveness of different treatment regimens.

03 Infectious Diseases

Clinical investigations into treatments for various infections, including bacterial infections and antibiotic resistance.

  • Staphylococcus Aureus Treatment
  • Urinary Tract Infections
  • Viral Lung Infections

Studies focusing on alternative antibiotics and novel approaches to combat resistant infections.

04 Mental Health Research

Studies examining innovative treatments for psychiatric disorders, including treatment-resistant conditions.

  • Schizophrenia Spectrum Disorders
  • Treatment-Resistant Depression
  • Novel Therapeutic Approaches

Investigating immunomodulatory treatments and new compounds for mental health conditions.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.